Regeneron Pharmaceuticals (STU:RGO) Construction In Progress: €0 Mil (As of Mar. 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
87 GF Score
Price €545.60
GF Value €786.86
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Construction In Progress?

Regeneron Pharmaceuticals STU:RGO -1.12% 87 Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 87/100 and a GF Value™ of €786.86 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Regeneron Pharmaceuticals's quarterly construction in progress increased from Sep. 2025 (€0 Mil) to Dec. 2025 (€1,614 Mil) but then declined from Dec. 2025 (€1,614 Mil) to Mar. 2026 (€0 Mil).

Regeneron Pharmaceuticals's annual construction in progress increased from Dec. 2023 (€1,233 Mil) to Dec. 2024 (€1,644 Mil) but then declined from Dec. 2024 (€1,644 Mil) to Dec. 2025 (€1,614 Mil).

Regeneron Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Construction In Progress Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 679.42 925.59 1,233.37 1,644.13 1,614.23

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1,614.23 0.00
STU:RGO
87GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0 Mil mean?
Regeneron Pharmaceuticals (STU:RGO) has a Construction In Progress of €0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Construction In Progress too high?
Regeneron Pharmaceuticals' current Construction In Progress is €0 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Construction In Progress compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Construction In Progress of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Construction In Progress is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Significantly Undervalued. The stock's GF Value™ is €786.86, compared to a current price of €545.60 — trading 30.7% below its estimated fair value. The current Construction In Progress is €0 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €545.60 is trading 30.7% below its estimated GF Value™ of €786.86. GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:RGO:

  • Construction In Progress: €0 Mil
  • GF Value™: €786.86 vs. price of €545.60 (30.7% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for STU:RGO

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€545.60
Price
€786.86
GF Value